

Comparing and contrasting predictive biomarkers for immunotherapy in of NSCLC

Nature Reviews Clinical Oncology

16, 341-355

DOI: [10.1038/s41571-019-0173-9](https://doi.org/10.1038/s41571-019-0173-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2019, 20, 3821.	1.8	116
2	Trial watch: dendritic cell vaccination for cancer immunotherapy. <i>Oncolimmunology</i> , 2019, 8, 1638212.	2.1	125
3	Antitumor activity of an engineered decoy receptor targeting CLCF1â€“CNTFR signaling in lung adenocarcinoma. <i>Nature Medicine</i> , 2019, 25, 1783-1795.	15.2	43
4	In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. <i>Cancers</i> , 2019, 11, 1271.	1.7	27
5	Next-generation computational tools for interrogating cancer immunity. <i>Nature Reviews Genetics</i> , 2019, 20, 724-746.	7.7	131
6	Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. <i>Molecular Cancer</i> , 2019, 18, 139.	7.9	156
7	Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 862.	1.3	28
8	Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 954.	2.2	89
9	<p>Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4893-4904.	0.9	10
10	The electronic nose: emerging biomarkers in lung cancer diagnostics. <i>Breathe</i> , 2019, 15, e135-e141.	0.6	15
12	Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China. <i>Journal of Ovarian Research</i> , 2019, 12, 117.	1.3	17
13	New Frontiers for Molecular Pathology. <i>Frontiers in Medicine</i> , 2019, 6, 284.	1.2	21
14	RNA sequencing for research and diagnostics in clinical oncology. <i>Seminars in Cancer Biology</i> , 2020, 60, 311-323.	4.3	56
15	Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 185-188.	1.2	13
16	The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced nonâ€“smallâ€“cell lung cancer: A systematic review and metaâ€“analysis. <i>Journal of Cellular Physiology</i> , 2020, 235, 4913-4927.	2.0	48
17	Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 1390-1398.	1.2	12
18	18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors. <i>PET Clinics</i> , 2020, 15, 11-22.	1.5	22
19	Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. <i>Cancer Letters</i> , 2020, 472, 108-118.	3.2	8

#	ARTICLE	IF	CITATIONS
20	Downregulation of MTHFD2 inhibits NSCLC progression by suppressing cycle-related genes. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1568-1577.	1.6	27
21	AKIP1 expression in tumor tissue as a new biomarker for disease monitoring and prognosis in non-small cell lung cancer: Results of a retrospective study. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23128.	0.9	7
22	Extracellular Vesicles in Non-Small-Cell Lung Cancer: Functional Role and Involvement in Resistance to Targeted Treatment and Immunotherapy. <i>Cancers</i> , 2020, 12, 40.	1.7	20
23	Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1. <i>Frontiers in Oncology</i> , 2020, 10, 549198.	1.3	2
24	Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer. <i>Cell</i> , 2020, 183, 303-304.	13.5	4
25	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	13.5	206
26	The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC. <i>Respiratory Research</i> , 2020, 21, 185.	1.4	10
27	Identification of an Immune Gene Expression Signature for Predicting Lung Squamous Cell Carcinoma Prognosis. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	4
28	Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy. , 2020, 8, e001392.		27
29	CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 6119.	5.8	53
30	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
31	Reply to: Problems With the Recommendations for PD-L1 Biomarker Testing. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, e65-e67.	0.6	0
32	LncRNA MIR210HG Facilitates Non-Small Cell Lung Cancer Progression Through Directly Regulation of miR-874/STAT3 Axis. <i>Dose-Response</i> , 2020, 18, 155932582091805.	0.7	17
33	<p>Long-Noncoding RNA CASC9 Promotes Progression of Non-Small Cell Lung Cancer by Promoting the Expression of CDC6 Through Binding to HuR</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9033-9043.	0.9	8
34	The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma. <i>Cell Cycle</i> , 2020, 19, 2918-2926.	1.3	3
35	USP29 enhances chemotherapy-induced stemness in non-small cell lung cancer via stabilizing Snail1 in response to oxidative stress. <i>Cell Death and Disease</i> , 2020, 11, 796.	2.7	22
36	Downregulation of ⁶A</sup> reader YTHDC2</sup> promotes tumor progression and predicts poor prognosis in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 3269-3279.	0.8	22
37	ERO1L promotes NSCLC development by modulating cell cycle-related molecules. <i>Cell Biology International</i> , 2020, 44, 2473-2484.	1.4	9

#	ARTICLE	IF	CITATIONS
38	Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China. <i>Journal of Translational Medicine</i> , 2020, 18, 320.	1.8	7
39	Molecular and Immune Characteristics for Lung Adenocarcinoma Patients With ERLIN2 Overexpression. <i>Frontiers in Immunology</i> , 2020, 11, 568440.	2.2	8
40	Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients. <i>Journal of Personalized Medicine</i> , 2020, 10, 208.	1.1	23
41	Molecular Profiling in Drug Development: Paving a Way Forward. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e309-e318.	1.8	5
42	Immuno-Oncology—The New Paradigm of Lung Cancer Treatment. <i>Current Oncology</i> , 2020, 27, 78-86.	0.9	18
43	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	0.5	182
44	Tumor-Derived Exosomes in Immunosuppression and Immunotherapy. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	85
45	Surface-Enhanced Raman Spectroscopy for Cancer Immunotherapy Applications: Opportunities, Challenges, and Current Progress in Nanomaterial Strategies. <i>Nanomaterials</i> , 2020, 10, 1145.	1.9	21
46	PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 83-87.	0.9	7
47	FKBP10 Regulates Protein Translation to Sustain Lung Cancer Growth. <i>Cell Reports</i> , 2020, 30, 3851-3863.e6.	2.9	19
48	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 111-138.	1.3	27
49	CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment. <i>Cancer Cell International</i> , 2020, 20, 106.	1.8	36
50	Toward Systems Biomarkers of Response to Immune Checkpoint Blockers. <i>Frontiers in Oncology</i> , 2020, 10, 1027.	1.3	16
51	Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103037.	2.0	47
52	High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms. <i>Endocrine Pathology</i> , 2020, 31, 264-273.	5.2	6
53	Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence images. <i>Methods in Enzymology</i> , 2020, 635, 33-50.	0.4	16
54	Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma. <i>Journal of Drug Targeting</i> , 2020, 28, 861-872.	2.1	11
55	STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. <i>ESMO Open</i> , 2020, 5, e000706.	2.0	139

#	ARTICLE	IF	CITATIONS
56	A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment. <i>Clinical and Translational Oncology</i> , 2021, 23, 434-449.	1.2	6
57	Lung cancer LDCT screening and mortality reduction – evidence, pitfalls and future perspectives. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 135-151.	12.5	234
58	Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. <i>Cancer Letters</i> , 2021, 500, 163-171.	3.2	55
59	YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer. <i>Cancer Letters</i> , 2021, 500, 51-63.	3.2	54
60	Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti-tumor immunity in non-small cell lung cancer. <i>Drug Development Research</i> , 2021, 82, 422-429.	1.4	16
61	Biology-guided radiotherapy: redefining the role of radiotherapy in metastatic cancer. <i>British Journal of Radiology</i> , 2021, 94, 20200873.	1.0	44
62	Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103194.	2.0	260
63	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1667-1678.	2.0	27
64	Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG trial). <i>Cancer Science</i> , 2021, 112, 388-396.	1.7	16
65	The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas. <i>Diagnostics</i> , 2021, 11, 196.	1.3	24
66	Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer. <i>Biomedicines</i> , 2021, 9, 48.	1.4	14
67	Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing. <i>Annals of Translational Medicine</i> , 2021, 9, 140-140.	0.7	4
68	Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers. <i>Frontiers in Immunology</i> , 2020, 11, 607416.	2.2	2
69	The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy. <i>BMC Cancer</i> , 2021, 21, 19.	1.1	24
70	The screening of immune-related biomarkers for prognosis of lung adenocarcinoma. <i>Bioengineered</i> , 2021, 12, 1273-1285.	1.4	22
71	Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. <i>Oncimmunology</i> , 2021, 10, 1909296.	2.1	13
72	PD-L1 expression in angiomatoid fibrous histiocytoma. <i>Scientific Reports</i> , 2021, 11, 2183.	1.6	3
73	Beyond DNA-targeting in Cancer Chemotherapy. <i>Emerging Frontiers - A Review. Current Topics in Medicinal Chemistry</i> , 2021, 21, 28-47.	1.0	6

#	ARTICLE	IF	CITATIONS
75	Exonuclease 1 (EXO1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Lung Adenocarcinoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1033-1048.	1.0	16
76	LncRNA EPIC1 promotes tumor angiogenesis via activating the Ang2/Tie2 axis in non-small cell lung cancer. <i>Life Sciences</i> , 2021, 267, 118933.	2.0	15
77	Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 585.	1.7	25
78	A Perspective of Epigenetic Regulation in Radiotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 624312.	1.8	19
79	Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 154.	1.1	23
80	Molecular Pathology in the New Age of Personalized Medicine. , 0, , .		2
81	Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1181-1200.	1.4	68
82	SLC7A7 is a prognostic biomarker correlated with immune infiltrates in non-small cell lung cancer. <i>Cancer Cell International</i> , 2021, 21, 106.	1.8	18
83	Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy. <i>BMC Bioinformatics</i> , 2021, 22, 127.	1.2	4
84	Nuf2 Is a Prognostic-Related Biomarker and Correlated With Immune Infiltrates in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 621373.	1.3	19
85	Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1256-1265.	1.3	9
86	A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	16
87	Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 596542.	1.3	6
88	Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 546455.	1.3	10
89	The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2021, 2021, 1-13.	0.9	15
90	Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry. <i>Translational Lung Cancer Research</i> , 2021, 10, 1679-1689.	1.3	8
91	The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements. <i>ESMO Open</i> , 2021, 6, 100087.	2.0	18
92	Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2022, 79, 4-17.	4.3	70

#	ARTICLE	IF	CITATIONS
93	ARH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. <i>Nature Communications</i> , 2021, 12, 2346.	5.8	52
94	Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 551-551.	0.7	5
95	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. <i>Npj Precision Oncology</i> , 2021, 5, 33.	2.3	5
96	GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 629333.	1.3	7
97	LINC00518 Promotes Cell Proliferation by Regulating the Cell Cycle of Lung Adenocarcinoma Through miR-185-3p Targeting MECP2. <i>Frontiers in Oncology</i> , 2021, 11, 646559.	1.3	5
98	Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC. <i>Frontiers in Oncology</i> , 2021, 11, 659321.	1.3	11
99	Comprehensive analysis of tumor microenvironment and identification of an immune signature to predict the prognosis and immunotherapeutic response in lung squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 569-569.	0.7	4
100	Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 591922.	1.3	8
101	TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin. <i>Molecular Pharmacology</i> , 2021, 100, 144-154.	1.0	6
102	Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer. <i>Respiratory Research</i> , 2021, 22, 189.	1.4	27
103	SLC15A4 Serves as a Novel Prognostic Biomarker and Target for Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 666607.	1.1	3
104	Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 684110.	1.3	14
105	Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy. <i>Genes and Immunity</i> , 2021, 22, 108-119.	2.2	17
106	The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1519-1530.	0.7	3
107	LncRNA CCDC144NL-AS1 Serves as a Prognosis Biomarker for Non-small Cell Lung Cancer and Promotes Cellular Function by Targeting miR-490-3p. <i>Molecular Biotechnology</i> , 2021, 63, 933-940.	1.3	23
108	Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2890-2916.	1.3	21
109	A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. <i>Oncogene</i> , 2021, 40, 4413-4424.	2.6	138
110	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. <i>Pharmacological Research</i> , 2021, 169, 105643.	3.1	13

#	ARTICLE	IF	CITATIONS
111	CoFe ₂ O ₄ -Quantum Dots for Synergistic Photothermal/Photodynamic Therapy of Non-small-Cell Lung Cancer Via Triggering Apoptosis by Regulating PI3K/AKT Pathway. <i>Nanoscale Research Letters</i> , 2021, 16, 120.	3.1	7
112	High expression of PIMREG predicts poor survival outcomes and is correlated with immune infiltrates in lung adenocarcinoma. <i>PeerJ</i> , 2021, 9, e11697.	0.9	4
113	Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3828.	1.7	6
114	Combined Assessment of Preoperative Frailty and Sarcopenia Allows the Prediction of Overall Survival in Patients with Lung Cancer (NSCLC) and Surgically Treated Brain Metastasis. <i>Cancers</i> , 2021, 13, 3353.	1.7	18
115	How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy. <i>Annals of Oncology</i> , 2021, 32, 833-836.	0.6	21
116	Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma. <i>Oncogenesis</i> , 2021, 10, 56.	2.1	5
117	A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor-Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy. <i>Cancers</i> , 2021, 13, 3751.	1.7	18
118	Proteome profiling of formalin-fixed, paraffin-embedded lung adenocarcinoma tissues using a tandem mass tag-based quantitative proteomics approach. <i>Oncology Letters</i> , 2021, 22, 706.	0.8	2
119	Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 4296.	1.7	15
120	Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC: Is Multiplex Immunohistochemistry or Immunofluorescence the Answer?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1247-1249.	0.5	2
121	The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC. <i>BMC Bioinformatics</i> , 2021, 22, 471.	1.2	2
122	Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 96.	1.3	5
123	Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. <i>Cancers</i> , 2021, 13, 4705.	1.7	86
124	Identification and Prognostic Value Exploration of Radiotherapy Sensitivity-Associated Genes in Non-Small-Cell Lung Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-14.	0.9	6
125	TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib. <i>Translational Oncology</i> , 2021, 14, 101163.	1.7	11
126	Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. <i>British Journal of Cancer</i> , 2021, 125, 1210-1216.	2.9	10
127	Artesunate-loaded porous PLGA microsphere as a pulmonary delivery system for the treatment of non-small cell lung cancer. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 206, 111937.	2.5	16
128	EGFR mutation is positively correlated with C-Met protein expression: a study of 446 resected lung adenocarcinoma. <i>Translational Cancer Research</i> , 2021, 10, 233-240.	0.4	0

#	ARTICLE	IF	CITATIONS
129	Identification of prognostic markers by weighted gene co-expression network analysis in non-small cell lung cancer. <i>Bioengineered</i> , 2021, 12, 4924-4935.	1.4	8
130	Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 593022.	1.3	9
131	Downregulation of long non-coding RNA LINC-PINT serves as a diagnostic and prognostic biomarker in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2021, 21, 210.	0.8	13
132	NUP37 silencing induces inhibition of cell proliferation, G1 phase cell cycle arrest and apoptosis in non-small cell lung cancer cells. <i>Pathology Research and Practice</i> , 2020, 216, 152836.	1.0	16
134	Eicosanoids in Cancer: New Roles in Immunoregulation. <i>Frontiers in Pharmacology</i> , 2020, 11, 595498.	1.6	68
135	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
136	Biomarkers of immunotherapy in non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	8
137	Mechanism of intrinsic resistance of lung squamous cell carcinoma to epithelial growth factor receptor-tyrosine kinase inhibitors revealed by high-throughput RNA interference screening. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	3
138	Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies. <i>Cureus</i> , 2020, 12, e8095.	0.2	19
139	SPTBN2, a New Biomarker of Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 754290.	1.3	9
140	Response to toripalimab combined with radiotherapy in advanced non-small cell lung cancer-not otherwise specified. <i>Medicine (United States)</i> , 2021, 100, e27581.	0.4	2
141	The genomic landscape of lung adenocarcinoma—insights towards personalized medicine. <i>Proceedings of the Indian National Science Academy</i> , 2021, 87, 562.	0.5	0
142	Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 $\geq 50\%$, but unanswered questions remain. <i>Annals of Translational Medicine</i> , 2019, 7, S127-S127.	0.7	7
144	Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer. , 2021, 9, e002989.		11
145	Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	8
146	USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1. <i>Cell Death and Disease</i> , 2021, 12, 1051.	2.7	23
147	Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration. <i>Pathology Research and Practice</i> , 2021, 228, 153680.	1.0	8
149	Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 507-516.	1.0	4

#	ARTICLE	IF	CITATIONS
150	Prediction of KRAS, NRAS and BRAF status in colorectal cancer patients with liver metastasis using a deep artificial neural network based on radiomics and semantic features. American Journal of Cancer Research, 2020, 10, 4513-4526.	1.4	5
151	SAEgnal: A Predictive Assessment Framework for Optimizing Safety Profiles in Immuno-Oncology Combination Trials. AMIA Summits on Translational Science Proceedings, 2021, 2021, 535-544.	0.4	0
152	High DSCC1 Level Predicts Poor Prognosis of Lung Adenocarcinoma. International Journal of General Medicine, 2021, 14, 6961-6974.	0.8	0
153	High DSCC1 Level Predicts Poor Prognosis of Lung Adenocarcinoma. International Journal of General Medicine, 2021, Volume 14, 6961-6974.	0.8	3
154	Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nature Cancer, 2021, 2, 1224-1242.	5.7	37
155	Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers. PLoS ONE, 2021, 16, e0260500.	1.1	2
156	Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing—a single-center experience. Translational Lung Cancer Research, 2021, 10, 4221-4234.	1.3	7
157	Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community. Journal of Thoracic Oncology, 2021, 16, 1976-1978.	0.5	1
158	Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation. Frontiers in Oncology, 2021, 11, 738832.	1.3	2
159	Identification of the ferroptosis-related long non-coding RNAs signature to improve the prognosis prediction and immunotherapy response in patients with NSCLC. BMC Medical Genomics, 2021, 14, 286.	0.7	7
160	Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology. Frontiers in Oncology, 2021, 11, 788245.	1.3	3
161	ZC3H12D is a prognostic biomarker associated with immune cell infiltration in lung adenocarcinoma. Translational Cancer Research, 2020, 9, 6128-6142.	0.4	2
162	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells, 2022, 11, 320.	1.8	43
163	A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer. Oncoimmunology, 2022, 11, 2028962.	2.1	26
164	Predictive value of TCR V β 2-J β 2 profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial. JCI Insight, 2022, 7, .	2.3	17
165	circRNA LDLRAD3 Enhances the Malignant Behaviors of NSCLC Cells via the miR-20a-5p-SLC7A5 Axis Activating the mTORC1 Signaling Pathway. Journal of Healthcare Engineering, 2022, 2022, 1-10.	1.1	2
166	CircFOXP1: A novel serum diagnostic biomarker for non-small cell lung cancer. International Journal of Biological Markers, 2022, 37, 58-65.	0.7	8
167	DOK5 as a Prognostic Biomarker of Gastric Cancer Immunoinvasion: A Bioinformatics Analysis. BioMed Research International, 2022, 2022, 1-22.	0.9	1

#	ARTICLE	IF	CITATIONS
168	Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity. <i>Frontiers in Immunology</i> , 2021, 12, 803014.	2.2	13
169	Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 817085.	1.8	5
170	Dysregulated transient receptor potential channel 1 expression and its correlation with clinical features and survival profile in surgical non-small cell lung cancer patients. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24229.	0.9	7
171	Immunotherapy in Lung Cancer: Current Landscape and Future Directions. <i>Frontiers in Immunology</i> , 2022, 13, 823618.	2.2	105
172	Identifying Actionable Variants Using Capture-Based Targeted Sequencing in 563 Patients With Non-Small Cell Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 812433.	1.3	0
173	Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes. <i>BMC Medicine</i> , 2022, 20, 64.	2.3	6
174	Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e16.	1.6	1
175	Analysis of miR-375-3p, miR-197-3p, and miR-15a-5p Expression and Their Clinical Relevance as Biomarkers in Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210809.	0.8	9
176	Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2022, 11, 277-294.	1.3	29
177	Docetaxel-Loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2022, 13, 832725.	1.6	5
178	Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 836891.	1.3	5
179	Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. <i>Cancer Cell</i> , 2022, 40, 289-300.e4.	7.7	148
180	Characterization of the Different Subtypes of Immune Cell Infiltration to Aid Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 758479.	1.8	1
181	Immunosuppressive properties of human PD-1 ^{hi} , PDL-1 ^{hi} and CD80 ^{hi} dendritic cells from lymph nodes aspirates of lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2469-2483.	2.0	3
182	N-Glycosylation at Asn291 Stabilizes TIM-4 and Promotes the Metastasis of NSCLC. <i>Frontiers in Oncology</i> , 2022, 12, 730530.	1.3	3
183	Inferring gene expression from cell-free DNA fragmentation profiles. <i>Nature Biotechnology</i> , 2022, 40, 585-597.	9.4	63
184	Role of FSCN1 in the tumor microenvironment of lung squamous cell carcinoma. <i>Immunobiology</i> , 2022, 227, 152206.	0.8	4
185	Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. <i>BMC Cancer</i> , 2021, 21, 1322.	1.1	7

#	ARTICLE	IF	CITATIONS
186	A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 219.	1.8	8
187	Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non-small Cell Lung Cancer PDX Models with Driver Genetic Alterations. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 359-370.	1.9	3
188	Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-10.	0.7	5
189	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. <i>MedComm</i> , 2021, 2, 692-729.	3.1	38
190	Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 5406-5429.	0.4	4
191	Single-Cell Digital Microfluidic Mass Spectrometry Platform for Efficient and Multiplex Genotyping of Circulating Tumor Cells. <i>Analytical Chemistry</i> , 2022, 94, 1108-1117.	3.2	25
193	Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report. <i>Frontiers in Pharmacology</i> , 2022, 13, 854277.	1.6	4
196	ROR1 agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 155.	3.5	11
197	Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France). <i>Cancers</i> , 2022, 14, 2258.	1.7	17
198	PCR-based analysis of PD-L1 RNA expression in lung cancer: comparison with commonly used immunohistochemical assays. <i>Annals of Diagnostic Pathology</i> , 2022, 59, 151968.	0.6	5
199	Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors. <i>Cancers</i> , 2022, 14, 2202.	1.7	3
200	TRPM3 antagonist Ononetin exerts anti-cancer effects on non-small cell lung cancer (NSCLC) by suppressing TGF- β 2 signaling. <i>Biochemical and Biophysical Research Communications</i> , 2022, , .	1.0	0
201	Serum transfer RNA-derived fragment tRFa31a79MP9P9NH57SD acts as a novel diagnostic biomarker for non-small cell lung cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, .	0.9	8
202	Effect of PPP1R14D gene high expression in lung adenocarcinoma knocked out on proliferation and apoptosis of DMS53 cell. <i>Clinical and Translational Oncology</i> , 2022, , .	1.2	1
203	Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up. , 2022, 10, e004412.		3
204	Added Value of Respiratory Gating in Positron Emission Tomography for the Clinical Management of Lung Cancer Patients. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 745-758.	2.5	6
205	Association between changes in thioredoxin reductase and other peripheral blood biomarkers with response to PD-1 inhibitor-based combination immunotherapy in non-small cell lung cancer: a retrospective study. <i>Translational Lung Cancer Research</i> , 2022, 11, 757-775.	1.3	5
206	M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2803-2814.	1.2	1

#	ARTICLE	IF	CITATIONS
207	Sesquiterpene from <i>Polygonum barbatum</i> disrupts mitochondrial membrane potential to induce apoptosis and inhibits metastasis by downregulating matrix metalloproteinase and osteopontin in NCI-H460 cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	1.4	0
208	Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 23-37.	2.0	4
210	Deep Learning CT Signature Predicts Benefit from Immunotherapy in Metastatic NSCLC Independent of Standard Clinicopathological Markers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
211	The feasibility of granzyme B levels using an amperometric immunosensor for lung cancer detection. <i>Annals of Translational Medicine</i> , 2022, 10, 622-622.	0.7	3
212	ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
213	Differential prognostic effect of systemic inflammation in patients with nonâ€‘small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 <sc>OAK</sc> trial. <i>Cancer</i> , 2022, 128, 3067-3079.	2.0	15
214	Folic acid-mediated MSNs@Ag@Geb multifunctional nanocomposite heterogeneous platform for combined therapy of non-small cell lung cancer. <i>Colloids and Surfaces B: Biointerfaces</i> , 2022, 217, 112639.	2.5	3
215	Molecular and Clinicopathological Characteristics of Lung Cancer Concomitant Chronic Obstructive Pulmonary Disease (COPD). <i>International Journal of COPD</i> , 0, Volume 17, 1601-1612.	0.9	2
216	LncRNA OIP5-AS1 Knockdown Facilitated the Ferroptosis and Immune Evasion by Modulating the GPX4 in Oesophageal Carcinoma. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-14.	0.7	9
217	Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
218	Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	4
219	Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. <i>International Immunopharmacology</i> , 2022, 110, 108985.	1.7	14
220	A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study. <i>EClinicalMedicine</i> , 2022, 51, 101541.	3.2	12
221	Host <sc>STING</sc> is essential for the efficacy of <sc>antiâ€‘PD</sc> â€‘1 inhibitors in nonâ€‘small cell lung cancer. <i>Immunology</i> , 0, , .	2.0	1
222	PD-1TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 4893-4906.	3.2	18
223	Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB. <i>Disease Markers</i> , 2022, 2022, 1-25.	0.6	7
224	Oncogene Overlap Analysis of Circulating Cell-free Tumor DNA to Explore the Appropriate Criteria for Defining MET Copy Numberâ€‘Driven Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 630-638.	1.1	2
225	Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
226	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
227	PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
228	Pan-Cancer Analysis of the Oncogenic and Immunological Role of Solute Carrier Family 6 Member 8 (SLC6A8). <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
229	Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9006.	1.8	9
230	The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer. <i>Modern Pathology</i> , 2022, 35, 1848-1859.	2.9	7
231	Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 146-159.	4.3	32
232	Integrating network pharmacology and transcriptomic validation to investigate the efficacy and mechanism of Mufangji decoction preventing lung cancer. <i>Journal of Ethnopharmacology</i> , 2022, 298, 115573.	2.0	5
233	Differential RNA expression of immune-related genes and tumor cell proximity from intratumoral M1 macrophages in acral lentiginous melanomas treated with PD-1 blockade. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166516.	1.8	0
234	Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 179, 103806.	2.0	14
235	Identification of metabolic genes for the prediction of prognosis and tumor microenvironment infiltration in early-stage non-small cell lung cancer. <i>Open Life Sciences</i> , 2022, 17, 881-892.	0.6	0
236	Lung Cancer Recurrence Risk Prediction through Integrated Deep Learning Evaluation. <i>Cancers</i> , 2022, 14, 4150.	1.7	1
237	Non-small-cell lung cancer patients harboring <i>TP53/KRAS</i> co-mutation could benefit from a PD-L1 inhibitor. <i>Future Oncology</i> , 2022, 18, 3031-3041.	1.1	1
238	Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	16
239	PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
240	FOXP family DNA methylation correlates with immune infiltration and prognostic value in NSCLC. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
241	Research Status of Mouse Models for Non-Small-Cell Lung Cancer (NSCLC) and Antitumor Therapy of Traditional Chinese Medicine (TCM) in Mouse Models. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-13.	0.5	3
242	An immunogold single extracellular vesicular RNA and protein (^{Au}SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	16
243	NEDD9 scaffolding protein expression as a negative prediction marker in non-small cell lung cancer (NSCLC). <i>Siberian Journal of Oncology</i> , 2022, 21, 47-55.	0.1	0

#	ARTICLE	IF	CITATIONS
245	Programmed cell death 1 inhibitor plus chemotherapy vs. chemotherapy in advanced drive-gene-negative non-small-cell lung cancer patients: A real-world study. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
246	NOX4 has the potential to be a biomarker associated with colon cancer ferroptosis and immune infiltration based on bioinformatics analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
248	High expression of glycolysis-related PGM2 gene in relation to poor prognosis and deficient immune cells infiltration in lung adenocarcinoma: a study based on bioinformatics analysis. <i>Journal of Thoracic Disease</i> , 2022, 14, 3488-3499.	0.6	1
249	Postoperative radiotherapy might be a risk factor for second primary lung cancer: A population-based study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
250	Application of Cytochrome C-Related Genes in Prognosis and Treatment Prediction of Lung Adenocarcinoma. <i>Disease Markers</i> , 2022, 2022, 1-19.	0.6	0
251	Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1664-1698.	1.3	1
253	Systems biology strategy and experimental validation to uncover the pharmacological mechanism of Xihuang Pill in treating non-small cell lung cancer. <i>Phytomedicine</i> , 2023, 108, 154491.	2.3	3
254	Combination of STING agonist and CXCR3 antagonist disrupts immune tolerance to overcome anti-PD-L1 resistance in lung adenocarcinoma under oxidative stress. <i>Gene</i> , 2023, 851, 146962.	1.0	1
255	A clinical risk model for assessing the survival of patients with stage IA-IIA non-small cell lung cancer after surgery. <i>Journal of Thoracic Disease</i> , 2022, 14, 4285-4296.	0.6	6
256	Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis. <i>Annals of Surgical Oncology</i> , 2023, 30, 1597-1613.	0.7	4
257	Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 1043-1055.	1.0	1
258	Biomarker testing of cytology specimens in personalized medicine for lung cancer patients. <i>Journal of Pathology and Translational Medicine</i> , 2022, 56, 326-333.	0.4	1
259	Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211417.	1.4	1
260	Single-cell transcriptional profiling uncovers the association between EOMES+CD8+ T cells and acquired EGFR-TKI resistance. <i>Drug Resistance Updates</i> , 2023, 66, 100910.	6.5	4
261	Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10. <i>Cancer Letters</i> , 2023, 555, 216025.	3.2	3
262	PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer—an IMMUNOTARGET case series. <i>Translational Lung Cancer Research</i> , 2021, .	1.3	1
263	Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
264	Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0

#	ARTICLE	IF	CITATIONS
265	Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	1
266	Integrated molecular analyses of an interferon- γ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. <i>Heliyon</i> , 2022, 8, e12102.	1.4	0
267	T Cell-Mediated Tumor Killing-Related Classification of the Immune Microenvironment and Prognosis Prediction of Lung Adenocarcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 7223.	1.0	1
268	Immune-related adverse events: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
269	Organoid technology and applications in lung diseases: Models, mechanism research and therapy opportunities. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	7
270	Effects of Lipid Metabolism-Related Genes PTCIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-31.	1.9	4
271	ULBP2 is a biomarker related to prognosis and immunity in colon cancer. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 2207-2219.	1.4	0
272	Silencing of circCRIM1 Drives IGF2BP1-Mediated NSCLC Immune Evasion. <i>Cells</i> , 2023, 12, 273.	1.8	3
273	Optimizing molecular testing of lung cancer needle biopsy specimens: potential solutions from an interdisciplinary qualitative study. <i>Respiratory Research</i> , 2023, 24, .	1.4	2
274	KRT17 serves as an oncogene biomarker of poor survival in patients with hepatocellular carcinoma. , 2023, 3, 18-25.		1
275	Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. <i>Cell Communication and Signaling</i> , 2023, 21, .	2.7	7
276	IKZF4 acts as a novel tumor suppressor in non-small cell lung cancer by suppressing Notch signaling pathway. <i>Cellular Signalling</i> , 2023, 107, 110679.	1.7	0
277	SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers. <i>IScience</i> , 2023, 26, 106027.	1.9	6
278	Identification of NLE1/CDK1 axis as key regulator in the development and progression of non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
279	CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
280	Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
281	Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. <i>PLoS ONE</i> , 2023, 18, e0277708.	1.1	3
282	Liquid biopsy-based identification of prognostic and immunotherapeutically relevant gene signatures in lower grade glioma. <i>Journal of Big Data</i> , 2023, 10, .	6.9	4

#	ARTICLE	IF	CITATIONS
283	ERCC6 plays a promoting role in the progression of non-small cell lung cancer. <i>Biochemistry and Cell Biology</i> , 0, , .	0.9	0
285	Cancer-Cell-Biomimetic Carbazole-Based AIE Nanoplatform for Targeted Phototheranostics of Lung Cancer. <i>ACS Applied Nano Materials</i> , 2023, 6, 6056-6065.	2.4	2
286	Programmable DNA Circuit-Facilitated Determination of Circulating Extracellular Vesicle PD-L1 for Lung Cancer Diagnosis and Immunotherapy Response Prediction. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 17696-17704.	4.0	1
289	Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Na ⁺ ve Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 2297.	1.7	3
290	Immunotherapy in Lung Cancer: Current Landscape and Analysis of Biomarkers. <i>World Journal of Cancer Research</i> , 2023, 13, 37-43.	0.1	0
291	Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. <i>Pathology Research and Practice</i> , 2023, 246, 154470.	1.0	0
292	Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
296	<i>Cancers bronchopulmonaires</i> . , 2023, , 195-197.		0